search
Back to results

The Effect of Metacognition-based, Manualized Intervention on Fear of Cancer Recurrence

Primary Purpose

Fear of Cancer Recurrence

Status
Recruiting
Phase
Not Applicable
Locations
Hong Kong
Study Type
Interventional
Intervention
ConquerFear Intervention
Active control: Basic Cancer Care
Sponsored by
The University of Hong Kong
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fear of Cancer Recurrence focused on measuring Fear of cancer recurrence, Metacognition, Cancer survivorship, Psychooncology, Breast cancer, Colorectal cancer, Gynecologic cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Cantonese- or Mandarin-speaking Chinese patients recently diagnosed with non-metastatic breast cancer, gynecologic cancer, or colorectal cancer
  2. had surgery as a primary treatment
  3. have had completed hospital-based adjuvant treatments including radiotherapy and chemotherapy within the past 18 months
  4. with the cut-off scored ≥ 13 on Severity, the subscale of Fear of cancer inventory
  5. are able to read and write Chinese
  6. are over the age of 18 years

Exclusion Criteria:

  1. non-Chinese ethnicity
  2. Patients diagnosed with metastatic cancer
  3. with a current diagnosis of depression or psychosis
  4. currently receiving psychological treatment
  5. with language difficulties or intellectual disability.

Sites / Locations

  • Queen Mary Hospital-Department of SurgeryRecruiting
  • Kwong Wah Hospital-Breast CenterRecruiting
  • Prince of Wales Hospital-Department of SurgeryRecruiting
  • Queen Mary Hospital-Department of Obstetrics & GynaecologyRecruiting
  • The University of Hong Kong Jockey Club Institute of Cancer CareRecruiting
  • Tung Wah Hospital-Department of SurgeryRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

ConquerFear Intervention

Basic Cancer Care

Arm Description

Participants in the ConquerFear intervention group will receive a manualized intervention, consisting of 6 therapist-led individual sessions.

Basic Cancer Care serves as an active comparator and is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 individual sessions including 2 relaxation training sessions, 2 dietetic consultation sessions, and 2 exercise sessions, which will be led by a trained therapist, a registered dietitian, and an exercise physiologist, respectively.

Outcomes

Primary Outcome Measures

Fear of cancer recurrence
The 42-items Fear of cancer recurrence inventory comprised of seven subscales will be used to assess the change of fear of cancer recurrence (FCR). Each item is rated on a 5-point Likert Scale with a total score ranging from 0 to 168. Higher scores indicate greater FCR. The subscale, Severity will be used as a screening tool for high level of FCR. A score of 13 or higher was optimal for screening.

Secondary Outcome Measures

Metacognitions
The 30-items Metacognitions questionnaire (MCQ-30) will be used to assess the change of metacognitive beliefs.Each item is rated on a 4-point Likert scale with a total score ranging from 30 to 120. High scores indicate a more maladaptive metacognitive style.
EORTC QLQ-C30
Quality of life (QoL) will be assessed by the EORTC QLQ-C30, in which incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhoea) and perceived financial impact of the disease.
Self-efficacy
Self-efficacy for managing chronic disease will be assessed using the Self-Efficacy for Managing Chronic Disease 6-item Scale.
Coping behavior
Coping behavior will be assessed using the 28-item Chinese Brief COPE.
Experimental avoidance
Experimental avoidance will be assessed using the Acceptance and action questionnaire.
Cognitive Attentional Syndrome
Cognitive Attentional Syndrome (CAS) will be assessed using the Cognitive-attentional Syndrome questionnaire (CAS-1).
Intolerance of uncertainty
Intolerance of uncertainty (IU) will be assessed using the 12-item Intolerance of uncertainty-12.
Psychological distress
Psychological distress will be assessed using the Hospital Anxiety and Depression Scale (HADS). HADS is a 14-item measure of anxiety and depression widely used to assess cancer-related distress.
Cancer-related distress
The 22-item Chinese Impact of Events Scale-revised (CIES-R) will be used to assess cancer-related distress, which comprised three subscales: avoidance, intrusive thoughts and hyperarousal symptoms measured using 5-point Likert scales. Higher mean scores on each subscale indicate greater avoidance/intrusiveness/arousal.
Treatment expectancy
Treatment expectancy will be assessed using the 6-item credibility/ expectancy questionnaire.
Therapeutic alliance
The 12-item Working Alliance Inventory (WAI-SF)will be used to assess agreement on the therapy goal, patients' agreement with the therapist, and quality of the interpersonal bond. Both the participants and therapists will be asked to fill in the WAI-SF immediate post-intervention
Treatment satisfaction
Treatment satisfaction will be assessed using the evaluation form. Participants will be asked to indicate their overall satisfaction with the intervention they have received.

Full Information

First Posted
September 22, 2020
Last Updated
September 28, 2023
Sponsor
The University of Hong Kong
Collaborators
Research Grants Council, Hong Kong
search

1. Study Identification

Unique Protocol Identification Number
NCT04568226
Brief Title
The Effect of Metacognition-based, Manualized Intervention on Fear of Cancer Recurrence
Official Title
The Effect of Metacognition-based, Manualized Intervention on Fear of Cancer Recurrence: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 21, 2021 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The University of Hong Kong
Collaborators
Research Grants Council, Hong Kong

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary aim of this study is to assess the effect of ConquerFear, a metacognition-based manualized intervention on fear of cancer recurrence, using the randomized controlled trial approach, among Chinese patients newly diagnosed with curable cancer. This study aims to (1) test the direct effect of ConquerFear intervention on fear of cancer recurrence and on maladaptive metacognition, and (2) to test the indirect effect of ConquerFear intervention on fear of cancer recurrence through its effect on maladaptive metacognition.
Detailed Description
A randomized controlled trial will be conducted to test the effect of a metacognition-based manualized intervention on fear of cancer recurrence among Chinese breast, gynecologic and colorectal cancer patients with high levels of fear of cancer recurrence. The aims are to test: the direct effect of ConquerFear intervention on fear of cancer recurrence, the direct effect of ConquerFear intervention on maladaptive metacognition the indirect effect of ConquerFear intervention on fear of cancer recurrence through its effect on maladaptive metacognition. Primary hypothesis: Participants in the ConquerFear intervention will show a greater reduction in fear of cancer recurrence compared to participants in the control group Participants in the ConquerFear intervention will show a greater reduction in maladaptive metacognition than the control participants There will be an indirect effect of ConquerFear intervention on fear of cancer recurrence through its effect on maladaptive metacognition.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fear of Cancer Recurrence
Keywords
Fear of cancer recurrence, Metacognition, Cancer survivorship, Psychooncology, Breast cancer, Colorectal cancer, Gynecologic cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
We will use a block randomization structure with randomly permuted block sizes of 2,4, and 6 to ensure a close balance of the numbers in each arm. Randomization (by a statistician) occurs prior to eligible patients attending the clinic to minimize opportunities for selection bias. We will also use a block randomization structure with randomly permuted block sizes of 4 and 8 to ensure an equal case allocation to each therapist. We will also use a block randomization structure with randomly permuted block sizes of 2,4, and 6 to ensure an equal case allocation to each dietitian.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
The investigator, care provider, and outcomes assessor are masked in terms of not knowing to which condition the participants will be randomized until after the completion of the baseline assessment. The outcomes assessor will break the envelope for the next eligible participant indicating if that participant is to be allocated to ConquerFear or control arms. The participants are masked in terms of not knowing that one intervention (i.e. Conquer fear) is hypothesized to yield larger effects than the other (i.e. control).
Allocation
Randomized
Enrollment
174 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ConquerFear Intervention
Arm Type
Experimental
Arm Description
Participants in the ConquerFear intervention group will receive a manualized intervention, consisting of 6 therapist-led individual sessions.
Arm Title
Basic Cancer Care
Arm Type
Active Comparator
Arm Description
Basic Cancer Care serves as an active comparator and is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 individual sessions including 2 relaxation training sessions, 2 dietetic consultation sessions, and 2 exercise sessions, which will be led by a trained therapist, a registered dietitian, and an exercise physiologist, respectively.
Intervention Type
Other
Intervention Name(s)
ConquerFear Intervention
Intervention Description
ConquerFear is a manualized intervention, consists of six individual sessions over 10 weeks. The key goals of this intervention are the following: (1) teach strategies for controlling worry and excessive threat monitoring, (2) modify underlying unhelpful beliefs about worry, (3) develop appropriate monitoring and screening behaviours, (4) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (5) clarify values and encourage engagement in values-based goal setting (19). Each session will last 60-90 minutes and be delivered by a trained therapist. After each session, participants will be given home-based exercises to practice the skills learned in the sessions. With the uncertainty surrounding the COVID-19 pandemic, instead of face-to-face sessions only, a hybrid mode of intervention delivery will be used by offering participants the choice of face-to-face or online sessions.
Intervention Type
Other
Intervention Name(s)
Active control: Basic Cancer Care
Intervention Description
Basic Cancer Care intervention for the control arm was developed to help cancer survivors with health maintenance in long-term through providing comprehensive lifestyle guidance. The intervention incorporates relaxation training, dietary and physical fitness consultations with the key goals to (1) teach relaxation techniques, (2) offer personalized diet and physical activity advice, and (3) enhance survivors' perceived control over illness, thereby leading to better adjustment to cancer. Similar to the ConquerFear intervention, Basic Cancer Care intervention consists of 6 individual sessions over 10 weeks. Each session will last 60-90 minutes and be delivered by a trained therapist, a registered dietitian, and an exercise physiologist, respectively. A hybrid mode of intervention delivery will be also used by offering participants the choice of face-to-face or online sessions.
Primary Outcome Measure Information:
Title
Fear of cancer recurrence
Description
The 42-items Fear of cancer recurrence inventory comprised of seven subscales will be used to assess the change of fear of cancer recurrence (FCR). Each item is rated on a 5-point Likert Scale with a total score ranging from 0 to 168. Higher scores indicate greater FCR. The subscale, Severity will be used as a screening tool for high level of FCR. A score of 13 or higher was optimal for screening.
Time Frame
Baseline, immediate post-intervention, 3months post-intervention, and 6months post-intervention
Secondary Outcome Measure Information:
Title
Metacognitions
Description
The 30-items Metacognitions questionnaire (MCQ-30) will be used to assess the change of metacognitive beliefs.Each item is rated on a 4-point Likert scale with a total score ranging from 30 to 120. High scores indicate a more maladaptive metacognitive style.
Time Frame
Baseline, immediate post-intervention, 3months post-intervention, and 6months
Title
EORTC QLQ-C30
Description
Quality of life (QoL) will be assessed by the EORTC QLQ-C30, in which incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhoea) and perceived financial impact of the disease.
Time Frame
Baseline, immediate post-intervention, 3months post-intervention, and 6months post-intervention
Title
Self-efficacy
Description
Self-efficacy for managing chronic disease will be assessed using the Self-Efficacy for Managing Chronic Disease 6-item Scale.
Time Frame
Baseline, immediate post-intervention, 3months post-intervention, and 6months post-intervention
Title
Coping behavior
Description
Coping behavior will be assessed using the 28-item Chinese Brief COPE.
Time Frame
Baseline, immediate post-intervention, 3months post-intervention, and 6months post-intervention
Title
Experimental avoidance
Description
Experimental avoidance will be assessed using the Acceptance and action questionnaire.
Time Frame
Baseline, immediate post-intervention, 3months post-intervention, and 6months post-intervention
Title
Cognitive Attentional Syndrome
Description
Cognitive Attentional Syndrome (CAS) will be assessed using the Cognitive-attentional Syndrome questionnaire (CAS-1).
Time Frame
Baseline, immediate post-intervention, 3months post-intervention, and 6months post-intervention
Title
Intolerance of uncertainty
Description
Intolerance of uncertainty (IU) will be assessed using the 12-item Intolerance of uncertainty-12.
Time Frame
Baseline, immediate post-intervention, 3months post-intervention, and 6months post-intervention
Title
Psychological distress
Description
Psychological distress will be assessed using the Hospital Anxiety and Depression Scale (HADS). HADS is a 14-item measure of anxiety and depression widely used to assess cancer-related distress.
Time Frame
Baseline, immediate post-intervention, 3months post-intervention, and 6months post-intervention
Title
Cancer-related distress
Description
The 22-item Chinese Impact of Events Scale-revised (CIES-R) will be used to assess cancer-related distress, which comprised three subscales: avoidance, intrusive thoughts and hyperarousal symptoms measured using 5-point Likert scales. Higher mean scores on each subscale indicate greater avoidance/intrusiveness/arousal.
Time Frame
Baseline, immediate post-intervention, 3months post-intervention, and 6months post-intervention
Title
Treatment expectancy
Description
Treatment expectancy will be assessed using the 6-item credibility/ expectancy questionnaire.
Time Frame
Baseline and immediate post-intervention
Title
Therapeutic alliance
Description
The 12-item Working Alliance Inventory (WAI-SF)will be used to assess agreement on the therapy goal, patients' agreement with the therapist, and quality of the interpersonal bond. Both the participants and therapists will be asked to fill in the WAI-SF immediate post-intervention
Time Frame
Immediate post-intervention
Title
Treatment satisfaction
Description
Treatment satisfaction will be assessed using the evaluation form. Participants will be asked to indicate their overall satisfaction with the intervention they have received.
Time Frame
Immediate post-intervention
Other Pre-specified Outcome Measures:
Title
Demographic data
Description
Demographic data including age, gender, marital status, education level, occupation and monthly family income will be assessed by self-reported questionnaire
Time Frame
Baseline
Title
Clinical data
Description
Clinical data will be extracted from medical records.
Time Frame
Baseline, immediate post-intervention, 3months post-intervention, and 6months post-intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Cantonese- or Mandarin-speaking Chinese patients recently diagnosed with non-metastatic breast cancer, gynecologic cancer, or colorectal cancer had surgery as a primary treatment have had completed hospital-based adjuvant treatments including radiotherapy and chemotherapy within the past 18 months with the cut-off scored ≥ 13 on Severity, the subscale of Fear of cancer inventory are able to read and write Chinese are over the age of 18 years Exclusion Criteria: non-Chinese ethnicity Patients diagnosed with metastatic cancer with a current diagnosis of depression or psychosis currently receiving psychological treatment with language difficulties or intellectual disability.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Danielle Wing Lam Ng, PhD
Phone
+852 39179897
Email
dwlng@hku.hk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wendy Wing Tak Lam, PhD
Organizational Affiliation
School of Public Health, The University of Hong Kong
Official's Role
Principal Investigator
Facility Information:
Facility Name
Queen Mary Hospital-Department of Surgery
City
Hong Kong
ZIP/Postal Code
000
Country
Hong Kong
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dominic Foo
Email
ccfoo@hku.hk
Facility Name
Kwong Wah Hospital-Breast Center
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vanessa Chun
Email
cok702@ha.org.hk
Facility Name
Prince of Wales Hospital-Department of Surgery
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Simon Ng
Email
simonng@surgery.cuhk.edu.hk
Facility Name
Queen Mary Hospital-Department of Obstetrics & Gynaecology
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karen Chan
Email
kklchan@hku.hk
Facility Name
The University of Hong Kong Jockey Club Institute of Cancer Care
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wendy Lam
Email
wwtlam@hku.hk
Facility Name
Tung Wah Hospital-Department of Surgery
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ava Kwong
Email
avakwong@hku.hk

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
All IPD that underlie results in a publication will be available from the PI upon reasonable request.
IPD Sharing Time Frame
Starting 6 months after publication
IPD Sharing Access Criteria
Information will be available from the PI upon reasonable request. The author to review requests is the PI.
Citations:
PubMed Identifier
31663187
Citation
Ng DWL, Foo CC, Ng SSM, Kwong A, Suen D, Chan M, Or A, Chun OK, Fielding BFS, Lam WWT. The role of metacognition and its indirect effect through cognitive attentional syndrome on fear of cancer recurrence trajectories: A longitudinal study. Psychooncology. 2020 Feb;29(2):271-279. doi: 10.1002/pon.5234. Epub 2019 Dec 23.
Results Reference
background
PubMed Identifier
30932279
Citation
Ng DWL, Kwong A, Suen D, Chan M, Or A, Ng SS, Foo CC, Fielding BFS, Lam WWT. Fear of cancer recurrence among Chinese cancer survivors: Prevalence and associations with metacognition and neuroticism. Psychooncology. 2019 Jun;28(6):1243-1251. doi: 10.1002/pon.5073. Epub 2019 Apr 26.
Results Reference
background
PubMed Identifier
29095681
Citation
Butow PN, Turner J, Gilchrist J, Sharpe L, Smith AB, Fardell JE, Tesson S, O'Connell R, Girgis A, Gebski VJ, Asher R, Mihalopoulos C, Bell ML, Zola KG, Beith J, Thewes B. Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence. J Clin Oncol. 2017 Dec 20;35(36):4066-4077. doi: 10.1200/JCO.2017.73.1257. Epub 2017 Nov 2.
Results Reference
background

Learn more about this trial

The Effect of Metacognition-based, Manualized Intervention on Fear of Cancer Recurrence

We'll reach out to this number within 24 hrs